Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

HIV (human immunodeficiency virus) immune purifier

A technology of AIDS and purification equipment, applied in the field of biomedicine, can solve the problems of rapid virus mutation, unsatisfactory effect, failure, etc., and achieve the effect of high concentration

Active Publication Date: 2017-01-04
ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role
During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone
Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, or it will mediate the ADCC effect to dissolve the cellular antigen by activating complement, but HIV does not Cellular antigens; either attract phagocytes to engulf antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and make them lose their infectivity, but the structure of HIV antigens is variable, often make it difficult for antibodies to recognize
[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure
(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance
(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart
(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed
(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly
[0008] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HIV (human immunodeficiency virus) immune purifier
  • HIV (human immunodeficiency virus) immune purifier
  • HIV (human immunodeficiency virus) immune purifier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] figure 1 It is an application schematic diagram of the AIDS immune purification instrument proposed according to the present invention.

[0014] figure 2 It is a schematic diagram of the internal structure of the blood separator proposed according to the present invention.

[0015] image 3 It is a schematic diagram of the internal structure of the plasma separator proposed according to the present invention.

[0016] Figure 4 It is a schematic diagram of the internal structure of the purifier proposed according to the present invention.

[0017] figure 1 Among them, one end of the arterial blood line tube (1) is connected with the arterial blood vessel, and the other end is connected with the blood separator (3) containing the waste liquid outlet (5) through the heparin and the blood pump (2), and the blood separator (3) is connected through the The blood outlet (4), the blood pump (6), and the circulation line (7) are connected to the plasma separator (8), and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Apertureaaaaaaaaaa
The average diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

An HIV (human immunodeficiency virus) immune purifier for the field of medical science is characterized in that a blood separator is prepared to filter multinuclear giant cells formed by lodging of HIV, a plasma separator is prepared to separate plasma and single blood cells, an HIV gp120 antibody and an HIVgp41 antibody capable of combining the HIV and HIV gp120 and gp41 antibodies capable of combining anti-goat Ig are prepared to serve as purifying agents distributed in agar gel, the agar gel is wrapped by high polymer materials to prepare the purifier, the purifier, the blood separator and the plasma separator jointly form critical components of an extracorporeal blood circulation device, the multinuclear giant cells containing the HIV are filtered when blood flows through the blood separator, the HIV is adsorbed and removed by the purifying agents when the plasma separated by the plasma separator flows through the purifier, and the purified plasma is converged with the single blood cells separated by the plasma separator and then returned into a body, so that HIV blood purification treatment of removing the HIV inside and outside the blood cells is achieved.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS immunopurification instrument in the field of biomedicine, which is mainly used for removing HIV inside and outside blood cells of AIDS patients, so as to achieve the purpose of preventing, controlling and treating AIDS. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tubercul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61M1/36C12M1/12C07K16/10
CPCA61M1/3612A61M1/3621A61M1/3635A61M1/3646A61M1/3687A61M2202/0415A61M2205/75C07K16/1063C12M47/04A61M2202/0021A61M2202/0028A61M1/3616
Inventor 翁炳焕李兰娟董旻岳李蓉虞晓鹏
Owner ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products